Mary Wilson
Well-known member
July 7, 2021
DOI: 10.1056/NEJMc2107799
(Authors listed below article in link)
TO THE EDITOR:
A second wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in India is leading to the emergence of SARS-CoV-2 variants. The B.1.617.1 (or kappa) and B.1.617.2 (or delta) variants were first identified in India and have rapidly spread to several countries throughout the world. These variants contain mutations within the spike protein located in antigenic sites recognized by antibodies with potent neutralizing activity.[SUP]1-3[/SUP] We used serum samples obtained from infected and vaccinated persons to assess neutralizing activity against the SARS-CoV-2 variants in a live-virus assay.
For the analyses, we used B.1.617.1 virus that had been isolated from a mid-turbinate swab obtained from a patient in Stanford, California, in March 2021 (hCoV-19/USA/CA-Stanford-15_S02/2021) and B.1.617.2 virus from a nasal swab that had been obtained from a patient in May 2021 (hCoV-19/USA/PHC658/2021). As compared with the WA1/2020 variant (nCoV/USA_WA1/2020; spike 614D), the B.1.617.1 and B.1.617.2 variants contain mutations in key regions within the spike, including the N-terminal antigenic supersite,[SUP]4[/SUP] the receptor-binding domain, and the polybasic furin cleavage site, [SUP]4[/SUP] the receptor-binding domain, and the polybasic furin cleavage site ...
https://www.nejm.org/doi/full/10.1056/NEJMc2107799
DOI: 10.1056/NEJMc2107799
(Authors listed below article in link)
TO THE EDITOR:
A second wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in India is leading to the emergence of SARS-CoV-2 variants. The B.1.617.1 (or kappa) and B.1.617.2 (or delta) variants were first identified in India and have rapidly spread to several countries throughout the world. These variants contain mutations within the spike protein located in antigenic sites recognized by antibodies with potent neutralizing activity.[SUP]1-3[/SUP] We used serum samples obtained from infected and vaccinated persons to assess neutralizing activity against the SARS-CoV-2 variants in a live-virus assay.
For the analyses, we used B.1.617.1 virus that had been isolated from a mid-turbinate swab obtained from a patient in Stanford, California, in March 2021 (hCoV-19/USA/CA-Stanford-15_S02/2021) and B.1.617.2 virus from a nasal swab that had been obtained from a patient in May 2021 (hCoV-19/USA/PHC658/2021). As compared with the WA1/2020 variant (nCoV/USA_WA1/2020; spike 614D), the B.1.617.1 and B.1.617.2 variants contain mutations in key regions within the spike, including the N-terminal antigenic supersite,[SUP]4[/SUP] the receptor-binding domain, and the polybasic furin cleavage site, [SUP]4[/SUP] the receptor-binding domain, and the polybasic furin cleavage site ...
https://www.nejm.org/doi/full/10.1056/NEJMc2107799